People, June, 2007

Wyeth has appointed three new directors. Nick Teague has become primary care director and has worked at Wyeth since 1989. Nick was previously assistant vice-president of commercial operations at Wyeth's European headquarters at Maidenhead.

Pierre van Weperen has become Enbrel director, and previously was Wyeth's director for specialist products in the Netherlands. Pierre has worked at Wyeth since 1999 in a number of sales and marketing management positions across a wide range of therapy areas, including infectious diseases, multiple sclerosis, rheumatology, dermatology, haemophilia, hypertension and diabetes. Claire Price has joined Wyeth as IT director. She joins from AstraZeneca where she was IT Infrastructure director for global sales and marketing.

Stuart Rose has been appointed managing director, UK & Ireland, of German pharma company Merz. He will be responsible for new product launches in both regions, and revenue growth. Stuart has 22 years' experience of pharmaceutical and consumer healthcare management and is former vice-president of sales and marketing, of Oxford Immunotech and founder of pharmaSMART Consulting.

Newron Pharmaceuticals, an R&D firm focused on CNS and pain therapies, has appointed Carlos de Sousa to the newly created position of chief business officer. Carlos has 19 years' experience in the pharma industry, working previously for 12 years at Pfizer and five years at Novartis. He had various roles including business development, clinical development and marketing at both companies. Most recently he was global head of business development and licensing at Schwarz Pharma.

Alltracel Pharmaceuticals has appointed Nick Hart as chief finance officer and executive director to its board. He will focus primarily on corporate activities including mergers and acquisitions. Alltracel has also announced the resignation of Irial Finan from the board. He has served as a non-executive director from 2004 and is stepping down because of increased demands of his executive commitments within the Coca Cola Group.

Otsuka Pharmaceuticals has made two new appointments: Ali Ross and David Lewis. Ali has been made associate director, communications, Europe. She will now head up the European communications and PR for Otsuka's European activities. Ali has worked for Otsuka for 14 years in the UK, US and Japan. David has been promoted to associate director and European brand leader for CNS at Otsuka Europe. David has worked at Otsuka for five years, firstly as marketing manager for the UK operation, then in a pan-European role.

Patricia A Steigerwald has been promoted to vice-president, global late phase at Kendle. She will provide executive leadership responsibility to drive continued growth in Kendleís Late Phase brand globally, with a focus on the design and conduct of phase IIB/IV clinical trials, health economics outcomes, research and product/disease registries. Patricia was most recently senior director of Late Phase at Kendle and has more than 20 years of CRO and clinical experience.

Affiniti has appointed Lisa Dodd as senior account director. Lisa worked previously at Matthew Poppy Ogilvy and Ogilvy Healthworld for eight years on campaigns for Abbott Laboratories, Serono, LEO, Pfizer and MSD. She is a qualified nurse and will bring strategic insight and therapeutic expertise in dermatology, oncology, urology and cardiovascular.

CeNeS Pharmaceuticals, a Cambridge-based biopharmaceutical company, has appointed its current director of drug discovery, Dr Gavin Kilpatrick, to the new position of chief scientific officer. Gavin has over 20 years' experience in CNS R&D and worked previously at the Institute of Psychiatry, Glaxo Wellcome and Roche. CeNeS has also appointed Keith Borkett as development director. Keith joined CeNeS in 2005 after over 20 years working in clinical development in large pharma companies including Roche, Amgen and Schering-Plough. Keith replaces Dr Terry Smith, who is retiring in June after being with the company since its formation in 1997. He will remain a senior consultant and member of CeNeS's Scientific Advisory Board.

Neil Betteridge, CEO of Arthritis Care, has been appointed first 'Patient and Public Champion' to monitor NHS efforts to reach the government's' target of reducinwaitintimes to 18 weeks. He will work closely with ministers and the NHS to ensure patients are at the centre of the 18-week pledge, and highlight their needs as reforms are implemented.

Julie Wheldon, previously science correspondent at the Daily Mail, is now account director in the healthcare division of PR company Manning, Selvage and Lee. Julie has eight years of journalism experience, and was health editor at the Daily Express and health correspondent at the Press Association.

Woolley Pau has appointed Shelley Jackman as account manager. She worked previously on ethical brands for Medicus London and has a degree in English Literature and Language.

The Chartered Institute of Marketing (CIM) has appointed Dr Ruth Ashford as its new chief examiner. Ruth's responsibilities will include making sure all CIM qualifications and exams are ratified, moderated and appropriate at the correct level. She will also manage all appeals and student disciplinary procedures, ensurinconsistency and fairness, and advise on assessment strategy and revisions. She has been a senior examiner for the institute since 1999. In addition, Dr Ahmad Jamal has taken over Ruth's previous role as senior examiner for marketing planning on the CIM's professional diploma in marketing, and Professor Keith Fletcher has been appointed the new director of education.

Hsdcommunications has promoted Lois McCloud to senior account executive after being at the company for two years working with a range of clients within the consumer health division. Lois will continue to work across two of the company's longest-standing client accounts, Potter's Herbal Medicines and Profoot, as well as supporting the healthcare communications agency's continued activities in Ireland.

Mover of the month: Harry Keenan

Baxter Healthcare has appointed Harry Keenan as general manager in the UK. Harry has worked for Baxter for 24 years, where he has held various strategic planning and sales and marketing roles in Belgium, Ireland and the UK, and was general manager for Greece/Ireland/Portugal based in Dublin.

MSA Market Media, formed by the merger of MSA Media and Market Media, has a new team with considerable experience in media planning and buying in the UK and abroad. Headed up by managing directors Emma Statham and Barry Hunt, the team comprises media directors Hilary Garside and Debbie Maxwell, account directors Sylvie Blackmore and Claire Deach, media manager Karen Field and financial controller Maria Jones.

"Is it an award winner? Don't show me unless it's an award winner." Exacting standards from a brilliant creative director who applied exactly the same principles to himself as he did to everyone in his department.

And began his advertising career in 1988 with placements at Foote Cone & Belding, KHBB, London and Harrison Cowley before joining BMP Countrywide. He enjoyed a successful career as an art director through BMP's various transitions to Palmer Hargreaves Wallis Tomlinson, when he became head of creative.

During this time, And worked on brands such as Ford, Jaguar Cars, Land Rover, Adam's Childrenswear, Avon Cosmetics, Mecca Bingo Clubs, Carlsberg, Tetley and Cadburys. His awards included a Midlands Cream Gold Award for Best Art Direction for Design Loake and a Silver Best TV for Warwick Castle.

And joined Langland as creative director in June 2003. He was a motivational force who inspired both creatives and clients alike. From the outset, his intent was to engage people to think about ethical pharmaceuticals as brands.

He wanted everyone to get excited about creating advertising that was original, impactful and differentiating. In 2006 alone, Langland won 31 creative awards under And's direction, including 13 at the IPA Best of Health Show, a record of which And was intensely proud.

On 17 March 2007, at the age of 39, And tragically and unexpectedly took his own life, leaving behind his wife Catherine and young daughter, Amber. Many tributes from clients, suppliers, and others who knew And have been sent to Langland since the news was announced. His "creative magic", "fiery passion" and "vibrant personality" are remembered, as well as his eye-catching taste in shirts. One correspondent in particular sums up how most feel: "His sudden passing is a real shock. He will be sorely missed not only for his genius and creativity, but for his humanity, his humour and his warmth as a person."

Langland is currently liaising with D&AD to establish a bursary in And's name, which will allow talented, young creatives to further their careers. A fitting legacy for a man whose passion for inspired creative thinking was second to none.